Citigroup began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.
Separately, J P Morgan Chase & Co assumed coverage on Apellis Pharmaceuticals in a report on Monday. They set an overweight rating and a $31.00 target price for the company.
Shares of Apellis Pharmaceuticals (NASDAQ APLS) opened at $13.60 on Monday. Apellis Pharmaceuticals has a twelve month low of $12.45 and a twelve month high of $15.41.
In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $1,785,210.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.